{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-001793","form_type":"8-K","ticker":"LIPO","cik":"0001347242","company_name":"LIPELLA PHARMACEUTICALS INC.","filed_at":"2024-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.231062+00:00","generated_at":"2026-05-30T06:52:20.738487+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lipella announces 1-for-8 reverse split effective Nov 7 to meet Nasdaq bid price","bullets":["Reverse stock split ratio of 1-for-8; effective 5:00 p.m. ET on November 7, 2024.","Common stock begins trading split-adjusted on November 8, 2024 under symbol LIPO.","Authorized shares unchanged at 200,000,000; par value remains $0.0001 per share.","Split intended to bring company into compliance with Nasdaq minimum bid price requirement.","Approved by stockholders at Annual Meeting on September 10, 2024; CUSIP changes to 53630L209."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-001793","json":"https://secwatch.observer/filing/0001753926-24-001793.json","markdown":"https://secwatch.observer/filing/0001753926-24-001793.md","text":"https://secwatch.observer/filing/0001753926-24-001793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347242/000175392624001793/0001753926-24-001793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347242/000175392624001793/g084523_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:52:20.738487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}